AlphaOnco

📍 Paris, France🗓 Founded 2008👥 2 employees💰 Last funded Nov 2012
Biotechnology Research🌐 alphaonco.fr
Website LinkedIn
AlphaOnco is pioneering a novel, non-invasive prostate cancer therapy using magnetosomes—naturally derived magnetic nanoparticles—combined with focused low-intensity ultrasound. This unique approach enables localized tumor destruction at moderate temperatures (45°C) without the need for general anesthesia, surgical procedures, or radiotherapy. The treatment is designed for outpatient use, significantly reducing cost, patient risk, and recovery time. With 15 global patent families, validated efficacy in multiple tumor models, and preclinical evidence showing full tumor disappearance with no regrowth, AlphaOnco is developing a new safe and efficient focal therapy of prostate cancer.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2008
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in AlphaOnco?
AlphaOnco has 1 investors on record on gritt.io, 1 mid-stage.
When did AlphaOnco last raise funding?
The most recent investment in AlphaOnco recorded on gritt.io was in November 2012.
When was AlphaOnco founded?
AlphaOnco was founded in 2008.
What industry is AlphaOnco in?
AlphaOnco operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AlphaOnco based?
AlphaOnco is headquartered in Paris, France.